Benzinga
Published Mar 27, 2024 15:00
Updated Mar 27, 2024 16:11
Performance Comparison: Abbott Laboratories And Competitors In Health Care Equipment & Supplies Industry
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Abbott Laboratories (NYSE:ABT) and its primary competitors in the Health Care Equipment & Supplies industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
Abbott Laboratories Background Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Abbott Laboratories | 34.20 | 5.01 | 4.86 | 4.19% | $2.77 | $5.68 | 1.49% |
Stryker Corp | 42.47 | 7.17 | 6.56 | 6.26% | $1.51 | $3.7 | 11.78% |
Medtronic PLC | 26.57 | 2.15 | 3.45 | 2.56% | $2.31 | $5.31 | 4.68% |
Boston Scientific Corp | 63.50 | 5.18 | 6.98 | 2.65% | $0.88 | $2.58 | 14.9% |
Becton Dickinson & Co | 55.48 | 2.76 | 3.60 | 1.1% | $1.03 | $2.03 | 2.62% |
Edwards Lifesciences Corp | 40.62 | 8.45 | 9.48 | 5.56% | $0.35 | $1.18 | 13.78% |
DexCom Inc | 107.66 | 26.08 | 16.44 | 11.82% | $0.3 | $0.66 | 26.9% |
IDEXX Laboratories Inc | 52.77 | 29.71 | 12.18 | 13.98% | $0.28 | $0.53 | 8.81% |
GE HealthCare Technologies Inc | 29.31 | 5.69 | 2.09 | 5.65% | $0.88 | $2.16 | 5.43% |
ResMed Inc | 32.15 | 6.37 | 6.36 | 4.78% | $0.39 | $0.65 | 12.48% |
Zimmer Biomet Holdings Inc | 26.20 | 2.10 | 3.63 | 3.35% | $0.58 | $1.4 | 6.3% |
Steris PLC | 38.93 | 3.41 | 4.09 | 2.24% | $0.36 | $0.6 | 14.77% |
Hologic Inc | 36.10 | 3.84 | 4.73 | 5.1% | $0.31 | $0.57 | -5.69% |
Shockwave Medical Inc | 82.10 | 17.68 | 16.54 | 6.98% | $0.06 | $0.18 | 40.93% |
Insulet Corp | 56.30 | 15.80 | 7.18 | 15.42% | $0.13 | $0.36 | 37.9% |
Teleflex Inc | 28.62 | 2.29 | 3.44 | 0.71% | $0.15 | $0.43 | 2.1% |
Penumbra Inc | 95.20 | 7.25 | 8.18 | 4.75% | $0.03 | $0.19 | 28.69% |
Masimo Corp | 93.16 | 5.45 | 3.72 | 2.57% | $0.06 | $0.26 | -11.04% |
Globus Medical Inc | 48.24 | 1.75 | 3.77 | 0.37% | $0.1 | $0.35 | 124.6% |
Integer Holdings Corp | 41.46 | 2.45 | 2.36 | 1.77% | $0.07 | $0.11 | 10.94% |
Average | 52.47 | 8.19 | 6.57 | 5.14% | $0.51 | $1.22 | 18.47% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } Through a thorough examination of Abbott Laboratories, we can discern the following trends:
The debt-to-equity (D/E) ratio is a key indicator of a company's financial health and its reliance on debt financing.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Abbott Laboratories can be assessed by comparing it to its top 4 peers, resulting in the following observations:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.